

1 Wastewater surveillance of human influenza, metapneumovirus, parainfluenza, respiratory
2 syncytial virus (RSV), rhinovirus, and seasonal coronaviruses during the COVID-19 pandemic
3

4
5 Alexandria B. Boehm^{1*}, Bridgette Hughes², Dorothea Doung², Vikram Chan-Herur², Anna
6 Buchman², Marlene K. Wolfe³, Bradley J. White²
7

- 8 1. Department of Civil & Environmental Engineering, School of Engineering and Doerr
9 School of Sustainability, Stanford University, 473 Via Ortega, Stanford, CA, USA 94305
10 2. Verily Life Sciences LLC, South San Francisco, CA, USA, 94080
11 3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
12 University, 1518 Clifton Rd, Atlanta, GA, USA, 30322
13

14
15
16 * Author to whom correspondence should be addressed. Email: aboehm@stanford.edu, Tel:
17 650-724-9128
18
19

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Abstract

Background: Respiratory disease is a major cause of morbidity and mortality; however, current surveillance for circulating respiratory viruses is passive and biased. Seasonal circulation of respiratory viruses changed dramatically during the COVID-19 pandemic. More active methods for understanding respiratory disease dynamics are needed to better inform public health response and to guide clinical decision making. Wastewater-based epidemiology has been used to understand COVID-19, influenza A, and RSV infection rates at a community level, but has not been used to investigate other respiratory viruses.

Methods: We measured concentrations of influenza A and B, RSV A and B, human parainfluenza (1-4), rhinovirus, seasonal human coronaviruses, and human metapneumovirus RNA in wastewater solids three times per week for 17 months spanning the COVID-19 pandemic at a wastewater treatment plant in California, USA. Novel probe-based assays were developed and validated for non-influenza viral targets. We compared viral concentrations to positivity rates for viral infections from clinical specimens submitted to sentinel laboratories.

Findings: We detected RNA from all target viruses in wastewater solids. Human rhinovirus and seasonal coronaviruses were found at highest concentrations. Concentrations of viruses correlated significantly and positively with positivity rates of associated viral diseases from sentinel laboratories. Measurements from wastewater indicated limited circulation of RSV A and influenza B, and human coronavirus OC43 dominated the seasonal human coronavirus infections while human parainfluenza 1 and 4A dominated among parainfluenza infections.

Interpretation: Wastewater-based epidemiology can be used to obtain information on circulation of respiratory viruses at a community level without the need to test many individuals because a single sample of wastewater represents the entire contributing community. Results from wastewater can be available within 24 hours of sample collection, allowing real time information to inform public health response, clinical decision making, and individual behavior modifications.

57 Introduction

58

59 Acute respiratory illnesses (ARI) are defined as symptomatic infections of the lower or upper
60 respiratory tract, and may also result in systemic symptoms and secondary infections. They are
61 consistently the top cause of illness and mortality in children under 5 globally after the neonatal
62 period, and represent a large burden of infectious disease¹. ARI etiology can be bacterial,
63 fungal, or viral; lower respiratory infections most commonly lead to severe conditions like
64 pneumonia and bronchiolitis, while upper respiratory infections are largely self limiting but can
65 result in secondary infections. Viral ARI are most commonly caused by SARS-CoV-2, seasonal
66 human coronavirus, human parainfluenza, human metapneumovirus, influenza, respiratory
67 syncytial virus, rhinovirus, adenoviruses, human bocaviruses, and non-rhinovirus
68 enteroviruses². In the United States, viral ARI causes nearly 400,000 child hospitalizations at a
69 cost of \$1 billion annually³.

70

71 Respiratory disease surveillance in the United States is passive and draws from many sources,
72 often relying on institutions to identify specific diseases through key words in clinical records,
73 testing of clinical specimens, and searching for keywords on death certificates. The passive
74 respiratory disease surveillance system is voluntary and biased towards identifying infections in
75 individuals with co-morbidities and/or where symptoms are severe and patients require clinical
76 care⁴. Since many ARIs are self-limiting, diagnostic testing of most individuals with respiratory
77 illness is uncommon. Lack of robust, unbiased data on disease occurrence and resultant lack of
78 knowledge on occurrence and trends in circulating respiratory diseases limits public health
79 response, institutional awareness that can guide clinical decision making regarding testing and
80 treatment, and efforts to understand disease epidemiology including disease interference and
81 co-infection⁵.

82

83 Prior to the COVID-19 pandemic, viral respiratory infections largely circulated seasonally with
84 predictable dynamics². However, seasonal occurrence of respiratory viruses has changed
85 dramatically during the COVID-19 pandemic⁶, presumably due to both imposed and voluntary
86 behavior changes in response to the pandemic, such as masking and stay-at-home orders⁷. It is
87 uncertain if and when respiratory disease dynamics will return to those observed pre-pandemic.
88 More active approaches to disease surveillance are needed to better understand and respond
89 to atypical respiratory disease dynamics.

90

91 Wastewater-based epidemiology (WBE) uses the information from wastewater to gain insight
92 into infectious disease occurrence in contributing communities. Wastewater represents a
93 composite biological sample containing bodily excretions including urine, feces, sputum, and
94 mucus. Excretions of infected individuals can contain markers of infectious disease (including
95 live and dead organisms, proteins and nucleic acids) and methods have been developed to
96 detect and quantify these in the wastewater matrix. Benefits of WBE are that it does not require
97 that infected individuals receive medical care or testing or even experience symptoms to be
98 represented in the community-level data source.

99

100 The utility of WBE has been demonstrated for understanding community circulation of
101 poliovirus⁸, *Salmonella*⁹, hepatitis A¹⁰, and enteroviruses¹¹, but its use has not widely been a
102 part of disease surveillance outside of polio in endemic regions. The application of WBE to
103 respiratory diseases is relatively new and was prompted by the COVID-19 pandemic, during
104 which it was widely shown that concentrations of SARS-CoV-2 RNA in wastewater correlate to
105 reported COVID-19 incidence rates during periods of widely accessible clinical testing¹².
106 Thereafter, Hughes et al.¹³ and Wolfe et al.¹⁴ showed RSV and influenza A RNA

107 concentrations, respectively, in wastewater solids were associated with disease occurrence in
108 associated sewersheds.

109
110 Here we test the utility of WBE for a suite of viral respiratory diseases. We developed and
111 validated novel hydrolysis probe-based RT-PCR assays that target respiratory viral genomes
112 and then applied the assays to wastewater solids collected three times per week at a
113 wastewater treatment plant over 17 months during the COVID-19 pandemic. We measured
114 concentrations of respiratory syncytial virus (RSV) A and B, influenza A and B,
115 metapneumovirus, parainfluenza (1-4), seasonal human coronaviruses (229E, OC43, NL63,
116 and HKU-1), and rhinovirus RNA. We chose to focus on these respiratory viruses as passive
117 clinical surveillance occurs for these diseases in the region where the sampling was conducted
118 allowing us to compare wastewater to clinical surveillance data. Additionally, these viruses
119 represent important and common viral etiologies of respiratory infections¹⁵.

120 121 **Methods**

122
123 **RT-PCR assays.** We used published hydrolysis probe-based RT-PCR assays for Influenza A
124 (IAV) and influenza B (IBV)¹⁶. We designed novel RT-PCR primers and internal hydrolysis
125 probes for rhinovirus (hereafter, “HRV” targeting rhinovirus A, B and C together); human
126 parainfluenza (HPIV) 1, 2, 3, 4A, 4B; human coronavirus (HCoV) 229E, NL63, OC43, HKU-1;
127 human metapneumovirus (HMPV); and Respiratory Syncytial Virus (RSV) A and B. To develop
128 the assays, viral genome sequences were downloaded from NCBI between between February
129 and June 2022 and aligned to identify conserved regions. Assays were developed *in silico* using
130 Primer3Plus (<https://primer3plus.com/>). Parameters used in assay development (e.g. sequence
131 length, GC content, and melt temperatures) are provided in Table S1. Primers and probes were
132 then screened for specificity *in silico*, and *in vitro* against virus panels, intact respiratory viruses,
133 synthetic viral genomic RNA, or cDNA sequences (see Supplementary Material (SM) including
134 Table S2).

135
136 **Wastewater analyses.** A wastewater treatment plant that serves 75% (1,500,000 people) of
137 Santa Clara County, California (San José-Santa Clara Regional Wastewater Facility, RWF) was
138 included in the study. Further descriptions of RWF can be found in elsewhere¹² .

139
140 Samples were collected daily for a COVID-19 WBE effort starting in November 2020¹², and a
141 subset of those samples (three samples per week, 216 samples total) are used in this study.
142 The samples were chosen to span a 17 month period (2/2/21 - 6/21/22, month/day/year format)
143 that included implementation and easing of indoor mask mandates, changes in COVID-19
144 vaccine availability, public health promotion of hand hygiene and mask wearing, and periods of
145 both high and low COVID-19 incidence.

146
147 Fifty mL of settled solids were collected using sterile technique in clean bottles from the primary
148 clarifier. Twenty-four hour composite samples were collected by combining grab samples from
149 the sludge line every six hours¹². Samples were stored at 4°C, transported to the lab, and
150 processed within six hours. Solids were then dewatered¹² and frozen at -80°C for 4 - 60 weeks.
151 Samples were thawed overnight and then RNA was obtained from the dewatered solids
152 following previously published protocols¹² (see SM). RNA was obtained from 10 replicate
153 sample aliquots. Each replicate RNA extract from each sample was subsequently processed
154 immediately to measure viral RNA concentrations using digital RT-PCR with multiplexed assays
155 for IAV, IBV, HMPV, total HPIV (HPIV 1, HPIV 2, HPIV 3, HPIV 4A, and HPIV 4B), total HCoV
156 (HCoV 229E, HCoV NL63, HCoV OC43, HCoV HKU-1), RSV A, RSV B, HRV, and pepper mild
157 mottle virus (PMMoV) (see SI). PMMoV is highly abundant in human stool and wastewater

158 globally¹⁷ and is used as an internal recovery and fecal strength control¹⁸ . Nine samples
159 spanning the duration of the time series were selected to measure each HCoV and HPIV
160 individually (Table S3). Each 96-well PCR plate of wastewater samples included PCR positive
161 controls for each target assayed on the plate in 1 well, PCR negative no template controls in two
162 wells, and extraction negative controls (consisting of water and lysis buffer) in two wells. PCR
163 positive controls consisted of viral gRNA or gene blocks (Table S2). Results from replicate
164 wells were merged for analysis. In order for a sample to be recorded as positive, it had to have
165 at least 3 positive droplets.

166
167 Concentrations of RNA targets were converted to concentrations per dry weight of solids in units
168 of copies (cp)/g dry weight using dimensional analysis. The total error is reported as standard
169 deviations and includes the errors associated with the Poisson distribution and the variability
170 among the 10 replicates. Three positive droplets across 10 merged wells corresponds to a
171 concentration between ~500-1000 cp/g; the range in values is a result of the range in the
172 equivalent mass of dry solids added to the wells.

173
174 **Wastewater SARS-CoV-2 N gene.** We obtained SARS-CoV-2 N gene concentrations at the
175 POTW from a regional monitoring program¹². These data were used in a supplementary manner
176 to provide insight into the progress of the COVID-19 pandemic (see SM).

177
178 **Clinical data.** California Sentinel Clinical Laboratories (hereafter, sentinel laboratories) test
179 clinical specimens for influenza A (IAV) and influenza B (IBV), respiratory syncytial virus (RSV),
180 parainfluenza viruses (HPIV) (1-4), human coronaviruses (HCoV) (229E, NL63, OC43, and
181 HKU-1), human metapneumovirus (HMPV), and rhinovirus (HRV). Sentinel laboratories do not
182 differentiate rhinovirus from other enteroviruses. Specimens tested by the laboratories may
183 represent inpatient or outpatient samples of people receiving medical care. Positivity rates were
184 calculated using data from all state sentinel laboratories and are reported by MMWR (Morbidity
185 and Mortality Weekly Report) week and assigned to the first day of MMWR week. Positivity
186 rates were also aggregated at the county-level for comparison (see SM).

187
188 **Statistical analysis.** Kendall's tau was used to test the null hypotheses (1) clinical specimen
189 positivity rates are not associated with viral concentrations in wastewater solids, and (2) viral
190 RNA concentrations were not associated with each other. Because case data are aggregated
191 by MMWR week, we used median wastewater measurements from the same MMWR week to
192 match clinical and wastewater data. To test correlations between wastewater viral RNA
193 concentrations, wastewater data were smoothed by calculating a rolling three-point median
194 (hereafter "smoothed wastewater concentrations"). A total of 50 Kendall's tests of association
195 were carried out so a p value of 0.001 was used to identify tau values significantly different from
196 0 based on Bonferroni's correction. To compare viral RNA concentrations visually on a similar
197 scale, we standardized their concentrations by subtracting the minimum and dividing by the
198 range.

199 **Results**

200
201
202 **QA/QC.** Results are reported as suggested in the EMMI guidelines¹⁹. All extraction and PCR
203 negative and positive controls performed as expected (negative and positive, respectively) with
204 the exception of the positive control failure for an HCoV run including samples before 2/26/22;
205 HCoV results prior to 2/26/22 were therefore omitted from the analysis. Median PMMoV
206 concentrations across the samples were 1.6×10^9 copies/g, similar to measurements previously
207 reported for the plant¹². In addition, PMMoV levels were stable across samples (interquartile

208 range = 0.7×10^9 cp/g) suggesting consistent fecal strength and RNA extraction efficiency. See
209 SM for additional QA/QC details.

210

211 **Novel assay sensitivity and specificity.** *In silico* analysis indicated no cross reactivity of the
212 novel RT-PCR probe-based assays (Table 1) with sequences deposited in NCBI. The novel
213 assays for HPIV, HMPV, HRV, and the HCoV were tested *in vitro* against panels of non-target
214 viral gRNA as well as target gRNA (Table S2). No cross reactivity was observed.

215

216 **Respiratory virus RNA in wastewater solids.** RNA from all viruses were detected in
217 wastewater samples (Figure 1). Concentrations varied from non-detect to over 10^6 copies/g. In
218 order of highest to lowest, median concentrations were 35000 cp/g for HCoV, 8500 cp/g for
219 HRV, 2500 cp/g for HPIV, 1700 cp/g for RSV B, 760 cp/g for HMPV, and non-detect for IAV,
220 IAB, and RSV A (Table 2). While median IAV, IBV, and RSV A were non-detect, viral RNA from
221 these viruses was detected in 28%, 6% and 14% of the samples, respectively. For context,
222 median concentrations for SARS-CoV-2 was 48000 cp/g. In general, concentrations were
223 lowest at the beginning of the study (February 2021), and increased until January 2022 at which
224 time viral RNA for all viruses showed a steep drop in concentration. Coincidentally, January
225 2022 marked the onset of the Omicron BA.1 wave in the region which caused the highest
226 COVID-19 reported incidence rates to date. After the steep drop off, viral RNA concentrations
227 began to rise until the end of the time series with the exception of RSV B for which we did not
228 observe a rebound. HCoV rebounded first when all other viral RNA concentrations, including
229 those of SARS-CoV-2, were still at relatively low concentrations (Figure 2).

230

231 In order to assess which HCoV were circulating during the study, we measured concentrations
232 of OC43, HKU-1, 229E, and NL63 RNA in nine samples spanning the time series (Figure 3).
233 Nearly 100% of the total HCoV RNA was OC43 RNA in seven of the nine samples, all collected
234 prior to April 2022. For the two samples collected thereafter, the contribution of OC43 RNA
235 declined to 20-30% and contributions of 229E and HKU-1 increased from <10% to greater than
236 50% and 20-30%, respectively.

237

238 Similarly, we measured RNA concentrations of each HPIV (1, 2, 3, 4A, and 4B) in samples
239 spanning the time series. RNA from all four HPIV were present; HPIV 3 dominated in most
240 samples (40-90% of total HPIVs), although each HPIV 2 and 4B also dominated in one of the
241 nine tested samples. HPIV 1 and 4A contributed the least to total HPIV present (median < 10%,
242 Figure 3).

243

244 **Associations between viral RNA and confirmed case positivity rates.** We tested whether
245 state-aggregated positivity rates for respiratory viral infections was associated with the
246 wastewater concentrations of viral RNA. Sentinel laboratories tested a median of 5918 (range
247 1809-14813) clinical specimens per week for influenza (IAV and IAB), 2419 (619-10907) for
248 RSV, 1084 (574 - 1984) for HPIV, HMPV, and HRV, and 931 (469-1833) for HCoV. The
249 associations between wastewater RNA concentrations and positivity rates were significant and
250 positive for all viruses except for IBV. Kendall's tau between positivity rates and wastewater
251 concentration were 0.36 ($p < 10^{-5}$) for HRV, 0.45 ($p < 10^{-5}$) for IAV, 0.52 ($p < 10^{-9}$) for HPIV, 0.57
252 ($p < 10^{-10}$) for RSV (using RSV B wastewater concentrations as RSV A was mostly non-detect),
253 0.32 ($p = 0.00018$) for HMPV, 0.32 ($p = 0.00011$) for HCoV, and -0.010 ($p = 0.92$) for IBV.
254 Wastewater concentrations and positivity rates aggregated across viruses were positively
255 correlated (tau = 0.50, $p < 10^{-15}$) (Figure S1). Results for county-aggregated positivity rates are
256 reported in the SM (Figure S2).

257

258 State-aggregated positivity rates for individual HCoV infections are similar to observations of the
259 relative occurrence of their RNA in wastewater solids (Figure 3). OC43 had the highest positivity
260 relative to other HCoV, in agreement with the wastewater measurements. Wastewater indicates
261 that 229E dominated at the end of the study (spring 2022), but this is not reflected in the clinical
262 data.

263
264 Positivity rates for individual HPIV suggests HPIV 3 dominated HPIV infections throughout the
265 study period; HPIV 2 and 4 also circulated with lower positivity rates. HPIV 1 was rarely
266 detected in clinical specimens. This is in agreement with the wastewater data that indicated
267 HPIV 3 dominated with HPIV 2 and 4B also present at relatively high levels, and HPIV 1 rarely
268 detected (Figure 3).

269
270 **Associations between wastewater viral RNA concentrations.** Viral RNA concentrations
271 were associated with each other, as well SARS-CoV-2 N gene concentrations available from a
272 regional monitoring program at the POTW (Table S4). Three-day smoothed wastewater
273 concentrations of HPIV, HRV, HMPV, IAV, RSV B, and SARS-CoV-2 RNA were significantly
274 correlated with each other ($p < 0.001$) with tau from 0.18 (IAV and HRV) to 0.61 (HRV and
275 HMPV). Given the low occurrence of IBV and RSV A RNA, it is not surprising that they were not
276 correlated with other viral RNA concentrations. HCoV RNA concentrations were not correlated
277 to concentrations of other viral RNA targets.

278
279 **Ethics.** This study was reviewed by State of California Health and Human Services Agency
280 Committee for the Protection of Human Subjects and determined to be Exempt.

281
282 **Role of funding source.** CDC Foundation played no role in study design, execution, or result
283 interpretation.

284 285 **Discussion**

286
287 We detected RNA from all tested respiratory viruses in wastewater solids, including human
288 rhinovirus, parainfluenza, metapneumovirus, influenza, respiratory syncytial virus, and seasonal
289 human coronaviruses. Additionally, we detected four types of seasonal human coronaviruses
290 including OC43, 229E, NL63, and HKU-1, and five different parainfluenza viruses (1, 2, 3, 4A,
291 and 4B). Non-influenza respiratory viral RNA targets were measured using novel assays; these
292 assays were found to be specific to the intended viral genomic targets when tested against a
293 range of viruses. Previous studies have documented human rhinovirus^{11,20}, RSV¹³, and
294 influenza¹⁴ RNA in wastewater, but to our knowledge, no study to date has reported
295 concentrations of other respiratory viruses.

296
297 RSV A RNA was rarely detected in wastewater, yet RSV B concentrations were $>10,000$ cp/g at
298 times, and RSV B wastewater trends mirrored RSV clinical surveillance data. This suggests
299 limited local co-circulation of the two RSV groups. Changes in dominant RSV strains have been
300 documented to occur at continental²¹ and community scales²² with resultant changes in
301 population immunity²³. Sequencing of SARS-CoV-2 in wastewater has been successful at
302 identifying variants²⁴, and sequencing of RSV genomes from wastewater may yield additional
303 insight into strain circulation and their potential susceptibility to different pharmaceutical
304 interventions.

305
306 The association between respiratory viral RNA in wastewater solids and their respective virus
307 clinical specimen positivity rates as available through a passive disease surveillance system
308 suggests that wastewater data are representative of respiratory disease occurrence in the

309 contributing population. This is despite limitations with passive disease surveillance, and the fact
310 that data were aggregated across the entire state which obfuscates disease occurrence
311 patterns at more local spatial scales. For example, state-aggregated HCoV case positivity
312 suggests OC43 infections dominated HCoV infections, yet wastewater solids measurements
313 suggest 229E dominated locally in spring of 2022. Similarly, based on wastewater
314 measurements, HPIV 1 and 4 may have contributed to more HPIV infections locally than on
315 average across the state.

316
317 There are uncertainties associated with understanding disease occurrence in a community
318 through both clinical surveillance and wastewater testing. Clinical surveillance data is biased
319 towards those receiving medical care and not all specimens are tested for all viruses, making it
320 difficult to estimate disease occurrence from positivity rate data. Positivity rates may not be
321 associated with disease occurrence in the same manner for all considered viruses. For
322 wastewater, there is limited information on concentrations of viral RNA excreted from infected
323 individuals into wastewater despite evidence showing that shedding does occur for viruses
324 included in this study^{25,26}. Given the current state of knowledge, it is difficult to know how inputs
325 of viral RNA to the wastewater system differ between individuals infected with different viruses
326 and with different disease severities.

327
328 Despite this, the association between viral RNA in wastewater solids and case positivity holds
329 when data from the measured viruses are aggregated, suggesting that even across
330 viruses, concentrations in wastewater solids are related to their different rates of disease
331 occurrence. HCoV and HRV concentrations were highest across our study period, suggesting
332 seasonal human coronavirus and human rhinovirus infections were most common. Conversely,
333 IBV and RSV A concentrations were lowest suggesting limited circulation of those viruses.
334 Future work is needed to document time varying patterns of respiratory viral RNA inputs from
335 infected individuals to the wastewater system to enable modeling of the number of infected
336 individuals in a sewershed from wastewater viral RNA concentrations²⁷ and to enable modeling
337 of epidemiological parameters like the reproductive number from wastewater data²⁸.

338
339 Viral RNA concentrations in wastewater solids, including those of SARS-CoV-2, generally
340 followed similar trends over time, with the exception of HCoV. Evident in the trends is a notable
341 drop-off in concentrations of all viruses after the Omicron BA.1 surge in January 2022. The
342 drop-off may suggest that disease mitigation measures practiced by the community in response
343 to the Omicron surge (isolation due to illness, working remotely, wearing masks) reduced the
344 spread of all respiratory viruses. Local indoor mask mandates ended shortly after the Omicron
345 surge, and this change was followed by an increase in concentrations of all respiratory viruses
346 in wastewater (Figure 3). HCoV, specifically OC43, was the first virus to re-appear in
347 wastewater after the Omicron surge. Non-SARS-CoV-2 HCoV are highly transmissible with R0
348 values higher, on average, than influenza and rhinovirus²⁹, but lower than RSV and similar to
349 HPIV; there is limited R0 data for HMPV¹⁵. It is also possible that infection with Omicron
350 reduced susceptibility to other respiratory viruses and contributed to the decrease in all viral
351 activity; antibody cross immunity has been suggested to control temporal patterns of some
352 respiratory viruses^{5,30}.

353
354 Data generated from wastewater can be available within 24 hours of sample collection, and
355 samples represent the entire contributing population - even those with asymptomatic infections
356 - thereby overcoming various biases and the inherent reporting delays of the passive
357 surveillance system. Wastewater surveillance for multiple respiratory viruses that commonly
358 circulate can provide information at a community scale on the most likely causes of ARI.
359 Although testing of clinical specimens is often not done for ARI, the viruses included in this


360 panel have differing levels of likely severity and associated prevention measures, treatments,
361 and complications. Therefore, more information about the abundances of circulating viruses can
362 inform local clinical decision making including the prescription of drugs and testing, availability of
363 community testing resources, and vaccination or behavior change campaigns. This information
364 can also be communicated to the public, like a weather report, so the community and
365 particularly vulnerable individuals can make informed decisions about behaviors that may put
366 them at risk.

367
368 **Acknowledgements.** This work is supported by a gift from the CDC Foundation. We
369 acknowledge Payal Sarkar at RWF for overseeing sample collection. We acknowledge Erin
370 Murray, Monica Sun, Tomás Leon, and Alexander Yu at California Department of Public Health
371 for their assistance. This study was performed on the ancestral and unceded lands of the
372 Muwekma Ohlone people. We pay our respects to them and their Elders, past and present, and
373 are grateful for the opportunity to live and work here.

374
375 **Declaration of interests.** BH, DD, VCH, ABu, and BW are employees of Verily Life Sciences,
376 LLC.


377
378 **Data sharing statement.** Wastewater data are available publicly at the Stanford Digital
379 Repository (<https://doi.org/10.25740/vx726fw9373>). State-aggregated surveillance data is
380 available upon request from California Department of Health.

381
382
383
384
385
386
387
388



389
 390 Figure 1. State-aggregated positivity rate reported as a percent from sentinel laboratories (top panel) and
 391 viral RNA in wastewater solids for each virus reported in copies per gram dry weight (bottom panel),
 392 exception is the top right panel which shows SARS-CoV-2 wastewater results for context. RSV is
 393 respiratory syncytial virus (A is shown in green and B in grey/black, RSV A scale is 1/10th that of RSV B
 394 and, like the RSV B axis, is scaled by 10^3), HCoV is the sum of all four seasonal human coronaviruses
 395 (OC43, HKU-1, 229E, and NL63), HPIV is human parainfluenza viruses (1-4), HRV is human rhinovirus A,
 396 B and C, HMPV is human metapneumovirus, and IAV and IBV are influenza A and B viruses,
 397 respectively. Gray symbols represent measurements, error bars are 68% confidence intervals
 398 representing the total error around 10 replicates. The black line is the 3-point rolling median of the
 399 measurements. For HCoV there are three measurements located off scale (1.1×10^6 , 3.6×10^5 , and 5.1×10^5
 400 cp/g on 4/9/21, 6/24/21, and 3/3/22, respectively). For HPIV there is one measurement located off scale
 401 (3.6×10^4 cp/g on 4/9/21). For HRV there is one measurement located off scale (3.6×10^5 cp/g on 4/14/22).
 402 For IAV there are 3 measurements located off scale (2.1×10^4 , 7.5×10^4 , 5.1×10^5 and 1.5×10^4 cp/g on
 403 9/30/21, 10/31/21, 3/3/22, and 4/14/22, respectively). Dates are in month/day/year format.


404
405



406
407
408
409
410
411
412
413
414
415

Figure 2. Standardized concentrations of viral RNA for all viruses except for RSV A and IBV which were rarely detected. Shaded background indicates periods of time that indoor masking mandates were in effect locally. Dates of COVID-19 vaccine availability are provided at top. Dates are in month/day/year format. Standardized concentrations were calculated by subtracting the minimum and dividing by the range. SC2 is SARS-CoV-2.

416
417
418



419
420
421
422
423
424
425
426

Figure 3. Data from wastewater solids on the (A) total concentration of HCoV RNA (shown as gray filled areas) and individual HCoVs (reported as fractions of total) and (B) total concentration of HPIV RNA (shown as gray filled areas) and individual HPIVs (reported as fractions of total). State-aggregated percent positivity for tests for (C) individual HCoVs and (D) individual HPIVs. Note that percent positivity for “unknown HCoV” and “unknown HPIV” from the sentinel surveillance system are not shown in panels C and D. Dates are in month/day/year format.

Target	Primer/Probe	Sequence
HRV	Forward	GCCYGCCTGGCKGCC
	Reverse	GAAACACGGACACCCAAAG
	Probe	TCCTCCGGCCCCTGAATG
HPIV 1	Forward	AAGTTCAGTACAAAGCGGGA
	Reverse	GCTCARTAGGGTTCTCCTA
	Probe	AGCAAAGCAGAGATCTCACACA
HPIV 2	Forward	AATACAACAGGGCARTGGG
	Reverse	GATAAAATAGCGTGAGGACTGC
	Probe	TCCTGTATATGGTGGTCTCATAAATGG
HPIV 3	Forward	TGTGGTGACCAACAGATCAA
	Reverse	CCCTCCAAAGAATCGTCCTG
	Probe	TCCAATGAAAACACTGATCCCAGA
HPIV 4A	Forward	TGAACGGTTGCATTCAGG
	Reverse	TTGACTGGTTGCACCTAATTCT
	Probe	CTGGCAATCTCAACATAGACCATG
HPIV 4B	Forward	GGAGAACTTTGAAACCACCTCTAA
	Reverse	TCTCCTTTAACTACCCTATCTTTGC
	Probe	ACCCCCATAAGGCAAGAAGC
HCoV 229E	Forward	GGATGACATCATGAAGGCAG
	Reverse	TACCCGTTTTCGCTGACTTT

	Probe	TTCCTGAGGCTTGTCAAACCT
HCoV NL63	Forward	GAAGCGTGTTCTACCAGAG
	Reverse	TGGCATCAACACCATTCTGA
	Probe	CAGTGCTTTGGTCCTCGTGA
HCoV OC43	Forward	GTCTTTTACTCCTGGTAAGCAATC
	Reverse	GGGTACAACATTCCCTCCTG
	Probe	CCGATCAGTCCGACCAGTTTAG
HCoV HKU-1	Forward	CCTGGTACGATTTTGCCTCA
	Reverse	ATTGGGTCCACGTGATTGAG
	Probe	AGGCTCAGGAAGGTCTGCTT
HMPV	Forward	ACTTTATTGGAGAAGGAGCAGG
	Reverse	GGGTAATGRTGATCAAGRTCA
	Probe	AYTGGATGGCMAGAACAGCA
IAV	Forward	CAAGACCAATCYTGTCACCTCTGA C
	Reverse	GCATTYTGGACAAAVCGTCTACG
	Probe	TGCAGTCCTCGCTCACTGGGCACG
IBV	Forward	TCCTCAAYTCACTCTTCGAGCG
	Reverse	CGGTGCTCTTGACCAAATTGG
	Probe	CCAATTCGAGCAGCTGAACTGCGGTG
RSV A	Forward	AGAGGTGGCAGTAGAGTTGA

	Reverse	CTCCACAACCTTGTTCCATTTCTG
	Probe	ATGGTGCAGGGCAAGTGATG
RSV B	Forward	TGACACTCCCAATTATGATGTGC
	Reverse	CCTGTGAATTTATGATTTGCATCTTCAG
	Probe	ACACCTAAACAACTATGTGGTATGC

Table 1. Primer and probe sequences for detection of respiratory viral RNA used in this study. Additional details of the target region of the genomes is the Supplementary Material. Primers and probes were purchased from IDT. All probes contained a fluorescent molecule and quenchers (5' FAM and/or HEX/ZEN/3' IBFQ). FAM, 6-fluorescein amidite; HEX, hexachloro-fluorescein; ZEN, a proprietary internal quencher from IDT; IBFQ, Iowa Black FQ. The Supplementary Material indicates whether HEX or FAM molecules were used.

Statistic	HPIV	HCoV	HMPV	HRV	RSV A	RSV B	IAV	IBV	SARS-CoV-2
median	3.5×10^3	3.5×10^4	7.6×10^2	8.5×10^3	0	1.7×10^3	0	0	4.8×10^4
25th %ile	1.4×10^3	1.7×10^4	0	4.6×10^3	0	0	0	0	2.5×10^4
75th %ile	6.3×10^3	5.6×10^4	2.0×10^3	1.7×10^4	0	5.4×10^3	6.6×10^2	0	1.3×10^5
# of ND	21	0	95	18	186	89	156	204	0
N	216	207	216	216	216	216	216	216	216

Table 2. Summary statistics of measurements of viral RNA in wastewater solids. Units of concentration is copies per gram dry weight of wastewater solids. RSV is respiratory syncytial virus, HCoV is the sum of all four non-SARS human coronaviruses (OC43, HKU-1, 229E, and NL63), HPIV is human parainfluenza viruses (1-4), HRV is human rhinovirus A, B and C, HMPV is human metapneumovirus, and IAV and IBV are influenza A and B viruses, respectively. SARS-CoV-2 data are included for context. # ND is number of samples for which the viral RNA was not detected. N is number of measurements made.

References

- 1 Wang H, Bhutta ZA, Coates MM, *et al.* Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016; **388**: 1725–74.
- 2 Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. *Annu Rev Virol* 2020; **7**: 83–101.
- 3 Henrickson KJ. Advances in the laboratory diagnosis of viral respiratory disease. *The Pediatric Infectious Disease Journal* 2004; **23**.
https://journals.lww.com/pidj/Fulltext/2004/01001/Advances_in_the_laboratory_diagnosis_of_viral.2.aspx.
- 4 Killerby ME, Biggs HM, Haynes A, *et al.* Human coronavirus circulation in the United States 2014–2017. *Journal of Clinical Virology* 2018; **101**: 52–6.
- 5 Nickbakhsh S, Mair C, Matthews L, *et al.* Virus–virus interactions impact the population dynamics of influenza and the common cold. *Proceedings of the National Academy of Sciences* 2019; **116**: 27142–50.
- 6 Kuitunen I, Artama M, Haapanen M, Renko M. Respiratory virus circulation in children after relaxation of COVID-19 restrictions in fall 2021—A nationwide register study in Finland. *Journal of Medical Virology* 2022; **94**: 4528–32.
- 7 Liu P, Xu M, Lu L, *et al.* The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID-19 pandemic. *Journal of Medical Virology* 2022; **94**: 4696–703.
- 8 Brouwer AF, Eisenberg JNS, Pomeroy CD, *et al.* Epidemiology of the silent polio outbreak in Rahat, Israel, based on modeling of environmental surveillance data. *Proc Natl Acad Sci USA* 2018; **115**: E10625.
- 9 Diemert S, Yan T. Clinically Unreported Salmonellosis Outbreak Detected via Comparative Genomic Analysis of Municipal Wastewater *Salmonella* Isolates. *Appl Environ Microbiol* 2019; **85**: e00139-19.
- 10 McCall C, Wu H, O'Brien E, Xagorarakis I. Assessment of enteric viruses during a hepatitis outbreak in Detroit MI using wastewater surveillance and metagenomic analysis. *Journal of Applied Microbiology* 2021; **131**: 1539–54.
- 11 Brinkman NE, Shay FG, Keely SP. Retrospective Surveillance of Wastewater To Examine Seasonal Dynamics of Enterovirus Infections. *mSphere* 2017; **2**: e00099-17.
- 12 Wolfe MK, Topol A, Knudson A, *et al.* High-Frequency, High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned Treatment Works in Northern California Shows Strong Association with COVID-19 Incidence. *mSystems* 2021; **0**: e00829-21.
- 13 Hughes B, Duong D, White BJ, *et al.* Respiratory Syncytial Virus (RSV) RNA in Wastewater Settled Solids Reflects RSV Clinical Positivity Rates. *Environ Sci Technol Lett* 2022; **9**: 173–8.
- 14 Wolfe MK, Duong D, Bakker KM, *et al.* Wastewater-Based Detection of Two Influenza Outbreaks. *Environ Sci Technol Lett* 2022; **9**: 687–92.
- 15 Leung NHL. Transmissibility and transmission of respiratory viruses. *Nature Reviews Microbiology* 2021; **19**: 528–45.
- 16 United States Center for Disease Control. Research Use Only CDC Flu SC2 Multiplex Assay Primers and Probes. 2022. <https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex-primer-probes.html> (accessed Aug 18, 2022).
- 17 Symonds EM, Nguyen KH, Harwood VJ, Breitbart M. Pepper mild mottle virus: A plant

- pathogen with a greater purpose in (waste)water treatment development and public health management. *Water Research* 2018; **144**: 1–12.
- 18 McClary-Gutierrez JS, Aanderud ZT, Al-faliti M, *et al.* Standardizing data reporting in the research community to enhance the utility of open data for SARS-CoV-2 wastewater surveillance. *Environ Sci: Water Res Technol* 2021; **7**: 1545–51.
- 19 Borchardt MA, Boehm AB, Salit M, Spencer SK, Wigginton KR, Noble RT. The Environmental Microbiology Minimum Information (EMMI) Guidelines: qPCR and dPCR Quality and Reporting for Environmental Microbiology. *Environ Sci Technol* 2021; **55**: 10210–23.
- 20 Blomqvist S, Savolainen-Kopra C, Paananen A, Hovi T, Roivainen M. Molecular characterization of human rhinovirus field strains isolated during surveillance of enteroviruses. *Journal of General Virology*,. 2009; **90**: 1371–81.
- 21 Cantú-Flores K, Rivera-Alfaro G, Muñoz-Escalante JC, Noyola DE. Global distribution of respiratory syncytial virus A and B infections: a systematic review. *null* 2022; : 1–12.
- 22 Peret TCT, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. *Journal of General Virology*,. 1998; **79**: 2221–9.
- 23 Melero JA, Moore ML. Influence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity. In: Anderson LJ, Graham BS, eds. *Challenges and Opportunities for Respiratory Syncytial Virus Vaccines*. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013: 59–82.
- 24 Crits-Christoph A, Kantor RS, Olm MR, *et al.* Genome Sequencing of Sewage Detects Regionally Prevalent SARS-CoV-2 Variants. *mBio*; **12**: e02703-20.
- 25 Branche AR, Walsh EE, Formica MA, Falsey AR. Detection of Respiratory Viruses in Sputum from Adults by Use of Automated Multiplex PCR. *Journal of Clinical Microbiology* 2014; **52**: 3590–6.
- 26 Minodier L, Charrel RN, Ceccaldi P-E, *et al.* Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? *Virology Journal* 2015; **12**: 215.
- 27 Soller J, Jennings W, Schoen M, *et al.* Modeling infection from SARS-CoV-2 wastewater concentrations: promise, limitations, and future directions. *Journal of Water and Health* 2022; **20**: 1197–211.
- 28 Huisman JS, Scire J, Caduff L, *et al.* Wastewater-based estimation of the effective reproductive number of SARS-CoV-2. *Environmental Health Perspectives* 2022; **In press**.
- 29 Spencer JA, Shutt DP, Moser SK, *et al.* Distinguishing viruses responsible for influenza-like illness. *Journal of Theoretical Biology* 2022; **545**: 111145.
- 30 Bhattacharyya S, Gesteland PH, Korgenski K, Bjørnstad ON, Adler FR. Cross-immunity between strains explains the dynamical pattern of paramyxoviruses. *Proceedings of the National Academy of Sciences* 2015; **112**: 13396–400.